[Transformation of gastrointestinal surgery diagnosis and treatment models]

In recent years, with the rapid development of medical device and biopharmaceutical technologies, the treatment model of gastric cancer surgery has been undergoing tremendous transformations. From the traditional open surgery model to the minimally invasive surgery model supported by devices such as laparoscopes and robots, the "precision minimally invasive" system integrated with 3D/4K high-definition imaging and fluorescent navigation has greatly expanded the capability boundaries of surgeons. Supported by the theory of high-throughput omics-based molecular typing of tumors, the clinical application of novel drugs such as immunotherapeutics and targeted drugs has further reshaped the treatment landscape of gastric cancer. The advancement of conversion therapy has significantly improved the therapeutic efficacy and prognosis of patients with locally advanced or distant metastatic gastric cancer, and the comprehensive treatment model that combines surgery with chemotherapy, radiotherapy, targeted therapy, immunotherapy and other modalities has become a mainstream trend. The role of surgical procedures is being redefined, and the concept of organ and function preservation has gained greater attention on the premise of ensuring oncological efficacy. Against the backdrop of the continuous evolution of gastric cancer diagnosis and treatment models, the establishment and practice of multidisciplinary treatment (MDT) and shared decision-making (SDM) models have become effective guarantees for enhancing the quality of gastric cancer diagnosis and treatment and improving patient prognosis. It is believed that the in-depth integration of cutting-edge technologies such as artificial intelligence with clinical medicine will enable the diagnosis and treatment of gastric cancer to enter the era of precision more rapidly.